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ABSTRACT 
Rotavirus (RV) causes severe life-
threatening diarrhea in young children and 
immunocompromised individuals.  There are 
several licensed attenuated vaccines for young 
children, but there are no vaccines or antiviral 
therapeutics for immunocompromised patients of 
any age.  Previously, our laboratory 
demonstrated that arachidin 1 (A1) and arachidin 
3 (A3) decreases the number of infectious simian 
RV particles and RV non-structural protein 4 
(NSP4) in a human intestinal cell line which 
suggests effects on RV replication.  This study 
examined the effects of the arachidins on the 
human RV (Wa)-infected African green monkey 
kidney cell line, MA104. The addition of either A1 
or A3 did not decrease the viability of MA104 
cells, however plaque forming assays measured 
significant decreases in the number of infectious 
RV particles with the addition of the arachidins.  
Correspondingly, western blot analyses revealed 
a change in the presence of VP6 and NSP4 
(structural and nonstructural RV proteins, 
respectively). This implies that like the simian 
RV, Wa replication is also affected by both A1 
and A3.  Additionally, tunable resistive pulse 
sensing technology (TRPS) measured changes in 
the population distribution of released 
nanoparticles between 60-140 nanometers.  
Additionally, TEM morphometric analyses 
showed ultrastructural changed in RV-infected 
cells treated with A1 or A3.   This included 
nucleus to cytoplasm ratios that were determined 
by TEM and whole cell fluorescent assays that 
disclosed significant nuclear size alterations with 
the addition of RV which implied modifications of 
the apoptosis and autophagy pathways.  
Moreover, the increased presence of autophagic 
vesicles seen with RV+A1 reinforced the model of 
a switch from the apoptosis to the autophagy 
pathway. In addition, immunoblot assays reveal 
the presence of cannabinoid 1 and 2 receptors on 
MA104 cells.  These receptors bind A1 and A3 
and are important in signaling in the 
endocannabinoid system.  This implies a role for 
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A1 and A3 in modulating cannabinoid receptor 
cell signaling in RV-infected cells which indicates 
a mechanism of action of A1 and A3 with 
potential RV therapeutic activity.  
INTRODUCTION 
Rotaviruses (RV) are members of the Reoviridae 
family that causes infantile gastroenteritis in children 
less than 5 years of age (Ward, 1996), and severe 
diseases in pediatric and adult immunocompromised 
individuals (Anderson & Weber, 2004; Bakare et al.,  
2010; Park et al., 2015; Patel et al., 2010; Yin, 
Metselaar, Sprengers, Peppelenbosch, & Pan, 2015). 
There are two licensed RV attenuated vaccines, 
RotaTeq® (Merck) and Rotarix® 
(GlaxoSmithKline), in the United States that prevent 
severe diarrhea (Leshem et al., 2014; Yen et al., 
2014), and an attenuated RV vaccine, Rotavac®, in 
India (Bhandari et al., 2014).  However, the vaccines 
efficacies are dependent on the timing of vaccination, 
and are designed to protect against common RV 
strains (Jiang et al., 2010; Patton, 2012).  Their 
efficacies are dependent on the genetic stability of 
the attenuated virus vaccines strains (Patton, 2012), 
but RV reassortments between RV strains are 
common and result in new infectious RV strains 
(Patton, 2012; Weinberg et al., 2013).  This could 
produce RV strains that are not affected by the 
vaccine strains. Furthermore, the vaccines are 
contraindicated for immunosuppressed individuals, 
and there are no antiviral therapeutic agents currently 
available for RV infections.  Besides the possibility 
of contracting RV-induced diarrhea directly from the 
infected individuals, there are documented cases of 
horizontal transmission of vaccine RV among 
immunocompromised household contacts from 
vaccinated children who shed the vaccine virus  
(Hsieh et al., 2014; Patel et al., 2010; Yen et al., 
2015).  Development of effective antiviral drugs that 
affect a wide-range of RV strains and reduces the 
burden of disease is an important strategy for the 
prevention of RV disease, especially in 
immunocompromised individuals. Likewise, the 
discovery of the antiviral mechanism(s) could lead to 
the development of compounds with a broad range of 
antiviral activity. 
Our laboratory is investigating the effects of 
highly purified stilbenoids extracted from peanut 
(Arachis hypogea) hairy root cultures on RV 
infections (Ball et al., 2015). Stilbenoids are 
secondary metabolites derived from plants that have 
antioxidant, anticancer, antifungal and anti-
inflammatory properties, and have shown many 
potential human health benefits (Aggarwal et al., 
2004; Athar et al., 2007; Roupe et al., 2006; Yang et 
al., 2017). They are products of the 
phenylpropanoid/acetate pathway and act as 
phytoalexins produced by plants such as grapes, 
berries, and peanuts in response to pathogens (Huang 
et al., 2010; Moss et al., 2013). Two prenylated 
stilbenoids, arachidin 1 (A1) and arachidin 3 (A3), 
significantly inhibit the production of infectious 
simian RV (SA114f) and show a reduction in the 
viral nonstructural protein, NSP4, which is critical 
for viral replication (Ball, et al., 2015).  Other studies 
have demonstrated that the activation of cellular 
signaling pathways is dependent on the RV strains 
and cell lines used in their experiments (Di Fiore et 
al., 2015; Halasz et al., 2010; Holloway et al., 2009; 
Holloway and Coulson, 2006; Otto et al., 2015; 
Saxena et al., 2016; Uzri and Greenberg, 2013).  
This study shows significant changes in the 
number of infectious human RV (Wa) particles 
produced with the addition of either A1 or A3 on the 
African green monkey kidney cell line, MA104.  
Correspondingly, western blot assays show changes 
in the presence of both structural and nonstructural 
RV proteins, VP6 and NSP4, respectively, 
suggesting an effect on progeny RV particles and 
replication. Additionally, tunable resistive pulse 
sensing technology (TRPS) using the qNano system 
by Izon revealed different patterns in the size 
 
 
3 
distribution of nanoparticles released from the 
arachidin treated, RV-infected MA104 cells.  
Transmission electron microscopy (TEM) was used 
to observe morphometric changes between the RV-
infected arachidin-treated cells, and the changes 
observed in the ratios of the nucleus to cytoplasm 
were substantiated with fluorescent-labeled whole 
cell assays. 
It is known that A1 and A3 bind to cannabinoid 
receptors which are important in the control of the 
endocannabinoid system. In this study, we revealed 
the presence of cannabinoid receptors 1 and 2 on 
MA104 cells.  This implies a role for A1 and A3 in 
modulating cannabinoid receptor cell signaling in 
RV-infected cells suggesting a mechanism of action 
of A1 and A3 with potential RV therapeutic activity   
MATERIALS AND METHODS 
Cell lines and virus. MA104 cells were obtained 
from ATCC (Rockville, MD) and maintained in 
Eagle Modified Essential Medium (MEM; Gibco, 
Grand Island, NY) supplemented with 5% fetal 
bovine serum (FBS), glutamine (2 mM), penicillin-
streptomycin (100 µg/mL) and non-essential amino 
acids (Sigma, St. Louis, MO as a 100X solution. The 
amino acids were used at a 1X concentration of 100 
µM each.) (Mitchell and Ball, 2004).   The cell line 
was confirmed to be free of mycoplasma 
contamination using the MycoFind mycoplasma 
PCR kit version 2.0 (Clongen Laboratories, LLC).  
RV Wa (G[1] P[8] genotype) was amplified 
(Matthijnssens et al., 2008).  Viral titers on virus 
stocks were determined in MA104 cells, followed by 
storage at -80°C.  Arachidin 1 and 3 efficacies 
against RV were tested using MA104 cells. 
Bioproduction of stilbenoids in hairy root cultures of 
peanut. Stilbenoids were produced as previously 
reported using the established hairy root line 3 from 
peanut cv. Hull (Condori et al., 2010) that was 
stimulated with the elicitor methyl-β-cyclodextrin 
(CD) (Cavasol® W7M)  (Yang et al., 2015).  A 72-
hour treatment of 9 g/L CD was selected based on the 
highest production of A1.  At day nine of the hairy 
root culture, the spent medium from each flask was 
removed and replaced with elicitation medium (fresh 
MSV medium with 9 g/L methyl-β-CD and 
incubated in the dark at 28oC for an additional 72 h 
to induce synthesis and secretion of stilbenoids into 
the culture medium as recently described (Yang et 
al., 2015).  After the elicitation period, the culture 
medium was removed from each flask and combined. 
This pooled medium was mixed with an equal 
volume of ethyl acetate in a separatory funnel to 
extract the stilbenoids as described previously 
(Condori et al., 2010).  The ethyl acetate phase was 
recovered and was dried in a rotavapor (Buchi), and 
A1 and A3 were purified from the extract by HPCCC 
as follows. The dried ethyl acetate extract was 
suspended in HPCCC solvent system (hexane: ethyl 
acetate: methanol: water [4:5:3:3]) and injected into 
a SpectrumTM (Dynamic Extractions) HPCCC 
system.  HPCCC fractions containing A1 and A3 
with over 95% purity based on HPLC analysis (UV 
340 nm) were combined, dried under a nitrogen 
stream and used for viral assays (Ball et al., 2015).  
As previously demonstrated, A1 and A3 were the 
major stilbenoids present in the culture medium, and 
the dry mass of each stilbenoid was reconstituted in 
0.02% DMSO in MEM medium (Ball et al., 2015). 
Viability Assay. Viability assays were performed as 
previously described using the Trypan blue cell 
exclusion assays (Ball et al., 2015; Freshney, 1994).  
MA104 cells were grown to 80% confluence in 6-
well tissue culture plates (Corning Life Sciences) and 
starved for fetal bovine sera 12 hours prior to the 
addition of RV alone, DMSO alone, RV + DMSO, 
RV + 20 µM A1, RV + 20 µM A3, 20 µM A3, 20 
µM A1 and NV (no virus).  At 18 hours post infection 
(hpi) a suspension of 106 cells/ml was diluted 1:1 
with a 0.4% Trypan blue solution and loaded onto a 
hemocytometer.  The number of stained cells and 
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total number of cells were counted, and the 
calculated percentage of unstained cells was reported 
as the percentage of viable cells. Each treatment was 
performed in triplicate, and data was expressed as the 
mean +/-standard deviation (SD).  Comparisons were 
statistically evaluated by a one-way analysis of 
variance (ANOVA) and Student’s t two tailed tests 
using Excel (significance level, p ≤ 0.05). 
RV Infections. To test the biological activity of the 
stilbenoids on RV infections, MA104 cells were 
grown to 80% confluence in 6 well tissue culture 
plates (Corning Life Sciences), starved for fetal 
bovine sera twelve hours prior to infection and then 
infected with RV (Wa) as previously described 
(Arnold et al., 2009; Ball et al., 2015; Yakshe et al., 
2015).  Rotavirus (Wa) stocks were sonicated for five 
minutes using a cup horn attachment with a Q500 
Sonicator (QSonica Sonicators, Newtown, CT), and 
incubated in serum-free MEM with 1 µg/mL trypsin 
(Worthington Biochemical, Lakewood, NJ) for 30 
min at 37°C. The activated viral inoculum was 
incubated with cells for 1 h at 37°C in 5% CO2 at 
multiplicity of infection (MOI) of 2. The inoculum 
was replaced with serum-free MEM supplemented 
with 1 µg/mL trypsin and incubated for 18 hpi. The 
supernatants were collected, clarified at 300 x g for 5 
min, and stored at -80°C for plaque assays and TRPS 
analysis (see below).  The cells were washed in cold 
1X Dulbecco's PBS (Caisson Laboratories, 
Smithfield, UT), and released from the plates using a 
0.25% Trypsin-EDTA Solution (Caisson 
Laboratories, Smithfield, UT).  After the addition of 
MEM with 5% FBS, the cells were suspended in cold 
1X PBS and dilutions were prepared for live/dead 
cell counts (see above in Viability Assays). For TEM 
analysis, approximately 2 x 106 cells were washed in 
cold 1X PBS, fixed with 5% glutaraldehyde and used 
for TEM analysis as described below. 
Infectious RV quantification. PFU assays were 
performed in triplicate as previously described 
(Arnold et al., 2009; Ball et al., 2015; Yakshe et al., 
2015).  Briefly, ten-fold dilutions of RV alone and 
RV with 0.002% DMSO and 20 µM A1 or A3 were 
added to the serum starved MA104 cells for one hour 
as described above. The virus inoculum was replaced 
with 3 mL of a medium overlay (1:1 mixture of 1.2% 
agarose [Apex Low Melting Point Agarose, Genesee 
Scientific Inc] and complete MEM containing 0.5 
µg/mL trypsin and incubated at 37°C in 5% CO2 for 
3 to 4 days or until plaques became visible.  A neutral 
red overlay (1:1 mixture of 1.2% agarose with an 
equal volume of serum-free MEM containing 50 
µg/mL neutral red) was prepared and 2 mL per well 
of stain overlay was added on top of the first 
agarose/medium overlay. The six-well plates were 
incubated at 37°C until plaques were visible 
(approximately 12 to 72 h).  The individual plaques 
were counted, and the titers were calculated as 
follows:  Number of plaques x 1/dilution factor x 1/ 
(mL of inoculum) = PFU/mL.  Plaque forming assays 
were performed in triplicate with data are expressed 
as mean +/-SD.  Comparisons were statistically 
evaluated by analysis of variance (ANOVA) and 
Student’s t two tailed tests using Microsoft Excel 
2011 software (significance level, p ≤ 0.05). 
Quantification and Size Distribution of RV Particles. 
To determine the concentration and size of 
nanoparticles released from the treated samples (RV, 
RV+A1 and RV+A3), TRPS analysis using the 
qNano system (Izon Science, Cambridge, MA) was 
employed.  TRPS is based on a coulter counter that 
is composed of two fluid reservoirs filled with an 
electrolyte or other conductive media and separated 
by a membrane containing a pore (Kozak et al., 2011; 
Weatherall et al., 2016).  When an electrical field is 
applied across the pore, the resistance to the resulting 
ionic current is indirectly proportional to the cross-
sectional area of the pore.  When a non-conducting 
particle passes through the pore, the increase in 
resistance is proportional to the particle volume 
relative to pore size. This change in resistance is 
detected as a pulse in an ionic current. The pulse 
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frequency is proportional to particle flow rate and 
particle concentration (DeBlois and Bean, 1970). 
This system provides a quick and accurate way to 
measure individual sizes of nanoparticles and their 
volume in a solution (Farkas et al., 2013; Vogel et 
al., 2011). All qNano experiments were performed 
using the manufacturer's established protocols (Bo et 
al., 2014; Jones, 2015; Vogel et al., 2011).  Prior to 
counting and measuring the particles, samples were 
purified using a qEV size exclusion column from 
Izon that contains a resin with an approximately 75 
nm pore size.  The purified particles samples were 
suspended in PBS with 0.025% Tween 20 to reduce 
particle aggregation and ease the wetting of the 
nanopore.  Dilutions of 1:1000 of the samples were 
placed on the qNano size-tunable nanopore (NP100, 
Izon), and each sample was measured as a transient 
change in the ionic current flow. This was denoted as 
a blockade event with its amplitude representing the 
blockade magnitude.  Because the blockade 
magnitude is proportional to the particle size, 
accurate particle sizing was achieved after 
calibration with 100 nm particles (CPC100B, Izon) 
using identical settings. The size distribution and 
concentration analyses were performed using IZON 
Science proprietary software v3.2.2.268. 
Morphometric analysis of RV-infected MA104 cells. 
TEM analysis was performed on RV-infected 
MA104 cells to visualize the effects of the A1 and 
A3 on progeny virus and cellular morphology. 
Samples were prepared as described (Wright, 2000).  
RV-infected MA104 cells with and without 20 µM 
A1 or A3 were incubated for 18 hpi, washed with 
PBS and then trypsinized.  Cells were pelleted and 
fixed with 5% glutaraldehyde overnight at 4°C. The 
cells were post-fixed with 2% osmium tetroxide, 
dehydrated with a graded ethanol series (15 - 30 
minutes incubation of the following: 30%, 50%, 
70%, 80%, 90%, and 100% ethanol), infiltrated and 
embedded in Spurr’s resin. Thin sections were 
stained with uranyl acetate and lead citrate and were 
examined with a Hitachi H-7000 electron 
microscope operating at 75 KeV. Negatives were 
digitized at 1200 dpi and analyzed using 
Macnification Version 2 (Orbicule, Inc., 
www.orbicule.com). RV particles were observed in 
RV-infected cells, and the average diameters of 
enveloped and non-enveloped particles were 
measured (n=23 particles for each group; the data 
was expressed and graphed as the mean +/- SD. Also, 
the mean the cell nucleus to cytoplasm ratios were 
determined using twelve micrographs of six 
treatment groups (No virus, RV, RV+A1, RV+A3, 
A1, A3).  All data were presented as the mean ± 
standard deviation. Statistical analyses were 
performed using one-way analysis of variance 
followed by Bonferroni's post hoc test using Excel. 
P<0.05 was considered to indicate a statistically 
significant difference. 
W1Xhole cell fluorescent labelling of nucleus and 
plasma membranes. The nucleus and plasma 
membranes of MA104 cells were fluorescently 
labelled to determine the ratios of the nucleus to 
cytoplasm of whole cells to compare to the nucleus 
to cytoplasm ratios obtained with TEM.  Briefly, 
MA104 cells were grown to 80% confluence in 8-
well slides (Lab-Tek Chamber Slide System, Nunc, 
Inc. Naperville, IL) and RV-infected and treated with 
the arachidins as described above (RV alone, RV 
with 20 µM A3 or A3, 20 µM A1 alone, or 20 µM 
A3 alone, and cells without treatments (NV-no 
virus). At 18 hpi, the cells were washed with 1X PBS  
one time at 25°C, and then fixed with 1% 
Glutaraldehyde (Electron Microscopy Science, 
Hatfield, PA) for one hour at 25°C in a fume hood 
(Harlow and Lane, 1988). Following fixation, the 
cells were washed twice with 1X PBS at 25°C.  The 
Image-IT™ LIVE Plasma Membrane and Nuclear 
Labeling Kit (I34406) (Molecular Probes, Invitrogen 
detection Technologies, Eugene, OR) was used to 
label the cells. Briefly, one solution for the single 
step staining for both stains was prepared by adding 
Witcher et al.: Arachidin-1 and Arachidin-3 Modulation of Rotavirus-infected MA10
 
 
6 
5.0 µg/mL Alexa Flour 594-labeled wheat germ 
agglutinin and 1 µM Hoechst 33342 stain into 1X 
PBS. One-hundred µLs of the labelling solution was 
added to each well in 8-well chambered slides, and 
incubated for ten minutes at 25ºC, removed and the 
cells were washed twice with 1X PBS, and mounted 
in 1X PBS. The microscopic analysis was carried out 
using the Olympus BX50 with DP Manager System 
compound light microscope with epifluorescence 
illumination for Alexa Fluor 594 labeled wheat germ 
(Excitation 480-550nm, dichroic mirror DM 570nm, 
barrier filter 590nm) and Hoechst 33342 (Excitation 
330-385nm, dichroic mirror DM 400nm, barrier 
filter BA420nm) with the DP71 camera (Olympus 
Corporation, Shinjuku, Tokyo, Japan) equipped with 
x 40 and X100 objectives. The images were digitized 
using the DP Controller software (Olympus 
Corporation), and the pixels of the nucleus and whole 
cell were measured using Macnification Version 2 
(Orbicule, Inc., www.orbicule.com). Excel was used 
to determine the nucleus to cytoplasm ratio of the 
cells of 45 to 56 cells per treatment. Data are 
presented as the mean ± standard deviation. 
Statistical analyses were performed using one-way 
analysis of variance followed by Bonferroni's post 
hoc test using Microsoft Office Excel 2016 software. 
P<0.05 was considered to indicate a statistically 
significant difference. 
Western blot and Immunoblot assays. For western 
blot analyses of RV proteins, 20 µg (to detect VP6) 
and 1 µg (to detect NSP4) of cell lysates were 
prepared and quantified as described above, 
separated by 12% SDS-PAGE, and electroblotted 
onto nitrocellulose membranes. The membranes 
were probed with a 1:1000 dilution of polyclonal 
rabbit serum anti-NSP4 (150-175) or polyclonal 
rabbit anti-VP6 specific antibodies (a gift from Dr. 
Judith M Ball), and reactive bands were visualized 
by the addition of 1: 5000 dilution (0.2ng/µl) HRP-
conjugated donkey anti-rabbit IgG (GE Health 
Sciences) with the addition of the Prometheus 
Protein Biology Products ProSignal Femto ECL 
Reagent (Genesee Scientific).  The digital images 
were captured using the Amersham Imager 600 (GE 
Healthcare UK Limited Amersham Place Little 
Chalfont Buckinghamshire HP7 9NA United 
Kingdom). The expression of GAPDH was used as a 
loading control on all western blots. Rabbit anti-
GAPDH (PA1-988, Thermo Fisher Scientific, 
Waltham, MA) was incubated at a 1: 5000 dilution 
(0.2ng/µl) and visualized for the viral proteins, VP6 
and NSP4, as described above for GAPDH. 
Cell lysates were prepared from treated and 
untreated MA104 cells, and total protein was 
quantified using a micro-BCA protein assay as 
previously described (Ball et al., 2015). For 
immunoblot assays, two-fold dilutions of RV-
infected and noninfected MA104 cell lysates (10, 5, 
2.5, 1.25 µg) were added to nitrocellulose 
membranes using a slot blot apparatus (Bio-Rad).  
Membranes were blocked with 10% nonfat dry milk 
and probed with a 1 µg/mL of rabbit anti-CNR1/2 
antibodies from Assay Biotechnology (Sunnyvale, 
CA), and incubated with 8 ng/mL of goat anti-rabbit 
IgG (H&L) Alexa Fluor 546 (Invitrogen, Carlsbad, 
CA).   Goat anti-rabbit Alexa Fluor®546-labelled 
antibodies (Life Technologies) were added and 
reactive bands were visualized using the 556 nm 
excitation laser and 573 nm emission filter on the 
Typhoon 9500 Plus laser scanner (GE Life Sciences, 
Marlborough, MA).  
RESULTS 
Viability of RV-infected MA104 cells in the presence 
of DMSO, A1, and A3.   
At 18 hpi, RV-infected cells showed an average 
viability of 89.46% (STD dev ± 5.6) and 
RV+0.002% DMSO showed 91.5% (STD dev ± 5.2) 
cell viability. Cells treated with RV+20 µM A1 
displayed a viability of 90% (std dev ± 0.6) and 20 
µM A1 alone had a 91.3% (std dev ± 2.6) viability.  
Cells treated with RV + 20 µM A3 displayed a 
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viability of 92.5% (std dev ± 2.6) and 20 µM A3 
alone had a 95.8% (std dev ± 2.6) viability. Untreated 
cells (no virus - NV) demonstrated 93% (std dev ± 
2.6, and NV+0.002% DMSO showed a viability of 
97.5% (std dev ±0.58). There were no statistical 
differences between all treatments except RV+A1 
was statistically different from A3 (P = 1.11E-4) and 
NV+0.002% DMSO (P = 1.31E-5) (Figure 1).  
 
  
Figure 1.  MA104 cell viability assay.  Trypan blue exclusion 
assays were performed in triplicate (RV, RV+0.002% DMSO, 
RV 20µM A1, 20µM A1, RV+20 µM A3, 20 µM A3, NV-no 
virus and NV+0.002% DMSO) at 18 hpi. The mean percent 
live/dead cells were calculated. Data were expressed as the 
mean ± SD, and comparisons were statistically evaluated with 
a one-way ANOVA and two-tailed Students’ 𝑡-tests followed 
by Bonferroni’s correction using Microsoft 2016 Excel 
software (significance level, P <0.05).  *Statistically different 
(RV+A1/A3) with P = 1.11E-4. **Statistically different 
(RV+A1/NV+0.002% DMSO) with P = 1.31E-5.    
 
The effects of A1 and A3 on the production of 
infectious RV particles.   
Supernatants were collected at 18 hpi from the RV-
infected and RV-infected with 20 µM A1 or A3 and 
used for plaque forming assays to quantify infectious 
RV particles.  Plaques were counted and the average 
of three experiments was calculated and graphed as 
PFU/mL (Figure 2). The PFU assays demonstrated a 
statistical difference in the production and release of 
infectious viral particles with the addition of A1 and 
A3.  At 18 hpi, RV only had a titer of 3.9E11, 
RV+A3 had a titer of 6.67E9, and RV+A1 had a titer 
of 7.11E9 (Figure 2).  This demonstrates a 59-fold 
and 55-fold reduction in PFU/ml in RV+A3 and 
RV+A1, respectively resulting in P = 1.356E-07 for 
both arachidins when compared to RV.  Both 
RV+A3 and RV+A1 showed no statistical difference 
from each other (P = 0.3731).  
 
 
Figure 2.  Plaque forming assays using supernatants from 
RV-infected and arachidin treated MA104 cells.  MA104 
cells were infected with Wa RV (Wa) at an MOI of 2 and treated 
with 20 µM A1 or A3. At 18hpi, the cell supernatants were 
collected, centrifuged, and serial diluted for plaque forming 
assays to determine the number of infectious viral particles/mL 
as plaque forming units (PFU/ml). Comparison of RV to 
RV+A1 and RV to RV+A3 both P = 1.356E-7.    
 
TEM viral particle size analyses of rv-infected 
ma104 cells.   
The presence of enveloped and nonenveloped RV 
particles was demonstrated in micrographs with a 
scale bar of 0.25 microns, and the less mature 
enveloped RV particle was shown entering the ER 
from a viroplasm (Figure 3A).  The average 
diameters of enveloped and non-enveloped RV 
particles were measured (n=20 particles for each 
group) (Figure 3B).  The less mature enveloped RV 
particles had a mean diameter of 112.736 ±3.20 and 
the more mature nonenveloped RV particles had a 
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mean diameter of 72.391 ± 2.172 nanometers which 
were statistically significant P = 1.2366E-34 (Figure 
3B). 
 
Figure 3.  Transmission electron micrograph (TEM) of Wa 
rotavirus infected MA104 cells at 18hpi. Final Magnification 
= 57,000x. A) Endoplasmic reticulum (ER), Viroplasm (V), 
Enveloped virus particles (E), and non-enveloped virus particle 
(NE). B)  Measurements of RV particles in TEM micrographs 
of MA104 cells infected with Wa rotavirus at 18 hpi (n = 20 per 
group).  Enveloped RV particles averaged 112.736 ± 3.20 
nanometers in diameter, and nonenveloped RV particles 
averaged 72.391 ± 2.172 nanometers in diameter (statistically 
significant P = 1.236E-34). 
 
TEM morphometric analyses of MA104 cells.  
Morphometric analyses using twelve TEM 
micrographs of each treatment groups.  The 
uninfected (NV-no virus), 20 µM A1 and 20 µM A3 
only treated MA104 cells were compared to RV 
infected cells as well as infected cells treated with A1 
or A3 at 18 hpi.  The three controls groups, no virus 
(NV), 20 µM A1, and 20 µM A3 (Figure 4A, 4B and 
4C, respectively) showed similar morphology.  
Conversely, the RV-infected cells demonstrated an 
increase in the size of the nucleus, many cytoplasmic 
vesicles and cytoplasmic blebbing (Figure 4D) 
which are characteristics of apoptosis (Elmore, 
2007).  However, RV-infected cells treated with A1 
and A3 (Figures 4E and 4F, respectively) appeared 
to have a more normal sized nucleus, and RV-
infected cells treated with A1 had many 
autophagosomes and large sized mitochondria-like 
organelles (M), while the A3 treated cells exhibited 
many small mitochondria-like organelles and many 
vesicles in the cytoplasm (Figures 4E and F). 
TEM analyses of MA104 cell nucleus to cytoplasm 
ratios.  The ratio of nucleus to cytoplasm was 
calculated using twelve representative cells from 
each treatment.  At 18 hpi, the mean ratios of the 
control cells treated with A1 (0.44±0.218) and A3 
(0.39±0.177) were like the cells with no treatment, 
NV (0.48±0.173) (Figure 5), while the RV-infected 
cells demonstrated an increased nucleus to 
cytoplasm ratio with a mean ratio of 1.31±0.347.  
RV-infected cells treated with A3 and A1 had mean 
ratios, 0.49±0.184 and 0.54±0.156, respectively, 
which were comparable to the ratios of the control 
cells.  However, both arachidin, treated RV-infected 
cells displayed different ultrastructure characteristics 
than the control cells.  RV-infected cells treated with 
A1 had many autophagosomes and large sized 
mitochondria, while the A3 treated cells exhibited 
many small mitochondria and many vesicles in the 
cytoplasm (Figure. 5). 
Fluorescent labelling of nucleus and plasma 
membrane.  MA104 cells treated with and without 
arachidins with and without RV were collected at 18 
hpi, fixed, and incubated with Alexa Fluor 594 wheat 
germ agglutinin (WGA) and blue-fluorescent 
Hoechst 33342 dye for selective staining of the 
plasma membrane and nucleus, respectively. After 
the cells were observed using the Olympus BX50 
with DP Manager System compound light 
microscope with epifluorescence, the pictures were 
digitized and the pixels of the nucleus and whole cell 
were measured using Macnification Version 2 
(Orbicule, Inc., www.orbicule.com).  Nucleus to 
cytoplasm ratios were calculated and statistical 
analyzed. 
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Figure 4.  Transmission electron micrograph (TEM) of Wa rotavirus (RV) infected MA104 cells at 18 hpi.  A) NV, no virus; B) 
A1 only; C) A3 only; D) RV only; E) RV+A1; F) RV+A3.  Scale bars equal 1-3 microns.  RV-infected cells (D) and RV+A3 (F) display 
many cytoplasmic vesicles (V) while RV+A1 has many autophagic vesicles (AP) and large mitochondria-like organelles (M).  RV+A3 
has many vesicles (V) and small mitochondria-like organelles (sM).  
 
 
 
 
Figure 5.  TEM nucleus to cytoplasm ratios of MA104. Cells 
were collected and processed for TEM analysis, and the areas 
of the nucleus and cytoplasm of ten micrographs for each 
treatment groups were measured with Macnification (Orbicule, 
Inc.). Nucleus to cytoplasm ratios were calculated and 
statistical analyses were performed. The data were analyzed by 
one-way analysis of variance (ANOVA) and two-tailed 
Student’s t tests (significance level, P < 0.05) with 
Bonferroni's post hoc test to correct for multiple comparisons.  
The data was graphed using a whisker and box plots.  The box 
represents all the data points within the lower (Q1) and upper 
(Q3) quartiles with vertical lines with an x that represents the 
median.  The whiskers go from each quartile to the minimum 
and maximum data points. Data points falling outside the 
overall pattern of distribution were plotted as dots that represent 
outliers.  * RV was statistically different from RV+A1 
(P=1.738E-05); RV+A3 (P=7.203E-06); NV (P=6.787E-06); 
A1 (P=3.479E-06); and A3 (P=1.976E-06). 
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Quantification of RV particles and size distribution 
by TRPS analysis.  TRPS analysis was performed on 
the RV infected cell supernatants (with and without 
treatments with A1 or A3) to display the 
concentration of virus particles/mL, diameter of RV 
particles and size distribution of particles. TRPS 
allow for high-throughput single particle 
measurements as virus particles are driven through 
pores, one at a time, causing a blockade event that 
can be measured for individual size; the number of 
blockades is used to determine the concentration 
(Vogel et al., 2011).  
   
Figure 6.  Nucleus to cytoplasm ratios of whole MA104. Cells 
were collected and fixed and stained with 5.0 µg/mL Alexa 
Flour 594-labeled wheat germ agglutinin to observe membranes 
and 1 µM Hoechst 33342 to visualize the nucleus. The 
microscopic analyses of 45-56 cells from each treatment groups 
were carried out using the Olympus BX50 microscope. The 
images were digitalized and the pixels of the nucleus (N) and 
whole cell were measured using Magnification Version 2 
(Orbicule, Inc., www.orbicule.com). The N/Cytoplasm ratios 
were analyzed by one-way analysis of variance (ANOVA) and 
two-tailed Student’s t tests (significance level, P < 0.05) with 
Bonferroni's post hoc test and graphed using a whisker and box 
plots. The box represents all the data points within the lower 
(Q1) and upper (Q3) quartiles with vertical lines with an x that 
represents the median. The whiskers go from each quartile to 
the minimum and maximum data points. Data points falling 
outside the overall pattern of distribution were plotted as dots 
that represent outliers. *RV was statistically different from 
RV+A1 (P=4E-22); RV+A3 (P=3.4E-20); NV (P=2.5E-21); 
A1 (P=3E-18); and A3 (P=1.4E-17). **NV was statistically 
different from A1 (P=1.4E-5); and ***NV was statistically 
different from A3 (P=5.5E-5). ****NV was statistically 
different from RV+A3 (P=0.0003). 
The RV only samples showed a concentration of 1.71 
x 1013 particles/mL at 18 hpi, and the particles had a 
dispersed range in diameter from approximately 60-
120 nm (Figure 7A).  At the same time, RV-infected 
cells treated with A3 showed a concentration of 4.25 
x 1012 particles/mL with the particle size diameters 
between 90-140 nm (Figure 7B).  Additionally, RV-
infected cells treated with A1 displayed a 
concentration of 1.42 x 1012 particles/mL with a 
population of particles between 70-150 nm (Figure 
7C). This reveals a shift in the size distributions of 
the populations of RV particles from a smaller size 
that is more consistent with mature infectious RV 
particles to larger, more immature RV particles with 
the addition of the arachidins. 
Western blot assays to detect rotavirus proteins.  
Western blots were performed to visualize the 
presence of RV nonstructural protein 4, NSP4 assays 
as previously described (Parr and Ball, 2003; Parr et 
al., 2006; Zhou, 2004) and the RV structural protein, 
VP6, in RV-infected cell lysates with/without 
treatment with arachidin 1(A1) or arachidin 3 (A3).  
Rabbit polyclonal antiserum to the SA11 NSP4 
synthetic peptide aa150-175 (αNSP4150-175) and 
polyclonal antiserum to VP6 was kindly provided by 
Dr. Judith Ball (Texas A&M Commerce, Commerce, 
TX) and rabbit anti-GAPDH antibodies were 
obtained from Thermo Fisher Scientific (Waltham, 
MA).  One microgram of the cell lysates was used 
for NSP4, and 20 µg of cell lysates were used to 
visualize VP6.  Results showed a band at ~36 kDa 
for GAPDH and ~42 kDa for VP6 (Figure 8A) and 
displayed NSP4-specific bands ~28 and 56 kDa, and 
a GAPDH-specific band ~36 kDa (Figure 8B). 
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Figure 7. TRPS analysis of arachidin treat MA104 cells. The size variations, virus concentrations and population distribution of 
extracellular RV particles were measured from supernatants of RV-infected cells treated with/without A1 and A3 at 18 hpi.  A) RV-
infected supernatants, B) Supernatants from RV-infected cells treated with 20 µM A1, and C) Supernatants from RV-infected cells 
treated with 20 µM A3 
 
 
 
 
Figure 8A.  The detection of the rotavirus structural protein 
VP6 in MA104 cells. Cell lysates (20 µg) were separated on a 
12% SDS/PAGE gel, electroblotted onto a nitrocellulose 
membrane, and probed sequentially with a 1:1000 dilution of 
rabbit anti-VP6 antiserum and a 1:5000 dilution (0.2ng/µl) of 
donkey anti-GAPDH antibody.  Amersham Rabbit IgG, HRP-
linked whole donkey antibodies were added at a 1:5000 dilution 
(0.2ng/µl), and the chemiluminescent detection was performed 
using the Prometheus Protein Biology Products ProSignal 
Femto ECL Reagent (Genesee Scientific) and Amersham 
imager 600. Results show a band at ~36 kDa for GAPDH and 
~42 kDa for VP6. 
 
Figure 8B.  The detection of the rotavirus nonstructural 
protein NSP4 in MA104 cells.   Cell lysates (1 µg) were 
separated on a 12% SDS/PAGE gel, electroblotted onto a 
nitrocellulose membrane. The membrane was probed 
sequentially with a 1:1000 dilution of rabbit anti-NSP4 antisera 
and a 1:5000 dilution (0.2ng/µl) of rabbit anti-GAPDH 
antibody. Rabbit IgG HRP-linked whole donkey antibodies 
were added at a 1:5000 dilution (0.2ng/µl), and the 
chemiluminescent detection was performed using the 
Prometheus Protein Biology Products ProSignal Femto ECL 
Reagent (Genesee Scientific) and Amersham imager 600. 
Results showed a band at ~36 kDa for GAPDH and ~28 and 56 
kDa for NSP4. 
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The presence of autophagy vesicles in rv infected 
ma104 cells treated with A1 or A3.  MA104 cells 
from each treatment (n = 12 each) were scored 
positive or negative for the presence of autophagic 
vesicles as demonstrated in Figure 4E.  Control cells 
(no virus – NV) showed autophagosomes in 23.1% 
of the observed cells, while 8.3% of the A3 alone 
treated cells and 66.7% of the A1 alone treated cells 
were positive for autophagic vesicles (Figure 9). 
 
Figure 9. Percent MA104 cells with autophagic vesicles at 18 
hpi.  TEMs of RV-infected, RV-infected arachidin treated, A1 
only, A3 and NV (no virus) cells were scored positive or 
negative for the presence of autophagic vesicles and the means 
for each treatment (n = 12) were compared in a graphed format.. 
Comparatively, 5.9% of the RV-infected cells, 
84.6% of RV-infected cells treated with A1, and 
7.7% of RV-infected cells treated with A3 were 
positive for autophagy vesicles (Figure 9). 
Immunoblot assays to detect cannabinoid receptors.  
Immunoblot assays were performed to confirm the 
presence of both A) cannabinoid receptor 1 (CBR1) 
and B) cannabinoid receptor 2 (CBR2) on MA104 
cells (Figure 10).  Both uninfected cell lysates 
(Figure 10A lane 1 and 10B lane 1) and RV-infected 
cell lysates (Figure 10A lane 2 and 10B lane 2) were 
positive for both receptors, and there appears to be a 
stronger signal with both CBR1 and CBR2 
antibodies from the RV-infected cell lysates (Figure 
8A lane 2 and 8B lane 2).   
  
Figure 10.  Cannabinoid Receptors 1 and 2 on MA104 cells. 
Two-fold dilutions of MA104 cell lysates (10 µg, 5 µg, 2.5 µg, 
1.25 µg) were added to nitrocellulose membranes [1-uninfected 
and 2-RV (Wa)-infected], probed with a 1:1000 dilution (1 
ng/µl) of rabbit anti-CBR1 (A) or anti-CBR-2 (B) antibodies 
from Assay Biotechnology (Sunnyvale, CA) and reactive bands 
were visualized by the addition and excitation of goat anti-
rabbit antibodies with Alexa Fluor®546 (Life Technologies) at 
a 1:5000 dilution (0.2ng/µl)  using the Typhoon 9500 Plus laser 
scanner. 
DISCUSSION 
A previous study in our laboratory has revealed that 
A1 and A3 reduce the amount of progeny infectious 
simian RV (SA11.4f) particles released from the 
human intestinal cell line (HT29.f8), thus suggesting 
a decrease in viral replication (Ball et al., 2015). This 
study investigated changes in a human RV (Wa)-
infected African green monkey kidney cell line, 
MA104, treated with either of the arachidins (A1 or 
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A3) at 18hpi.  Our hypothesis was that the human RV 
(Wa) replication would be inhibited, and that the 
ultrastructure of the MA104 cells would be affected 
by the arachidins.   
The viability assay verified that there were no 
toxic effects on the MA104 cells treated with either 
of the arachidins (A1 and A3), therefore 20µM 
concentrations of A1 and A3 and 0.002% DMSO, 
which was used to solubilize the arachidins, are 
nontoxic to MA104 cells. It was interesting to 
observe a significantly increased viability with the 
addition of DMSO to the untreated cells when 
compared to RV-infected cells treated with A1 or 
A3.  Although there were no significant differences 
between RV-infected (no DMSO) and RV-infected 
cells treated with A1 or A3, there was a significant 
difference between RV-infected cells treated with 
A1 and uninfected A3 treated cells, and significant 
difference between RV-infected cells treated with 
A1 and NV with DMSO.  This infers a possible 
difference in how A1 modifies an RV infection 
versus noninfected MA104 cells treated with A1 or 
DMSO alone. 
Likewise, the decreased amount of infectious 
RV produced in Wa-infected arachidin treated 
MA104 cells resembled the decrease in progeny RV 
produced in the simian RV, (SA11.4f)-infected 
human intestinal cell line (HT29.f8) with arachidin 
treatments (Ball et al., 2015). This indicated that A1 
and A3 have antiviral properties that effect both 
simian and human RV strains in both African green 
monkey kidney (MA104) and human intestinal 
(HT29.f8) cell lines.   
TEM examination of intracellular RV particles 
demonstrated two size populations; the more mature 
nonenveloped (neRV) that are of similar sizes of 
mature infectious RV particles and the less mature 
enveloped (eRV) (Estes and Greenberg, 2013). At 
the same time point (18hpi), TRPS analysis of 
extracellular nanoparticles (50-150nm) using the 
Izon qNano system revealed relatively equal number 
of extracellular particles among treatments with and 
without arachidins, however the size distribution of 
the particles varied significantly. It is notable that the 
virus particles observed in the MA104 cells were 
similar in size to the nanoparticles observed outside 
the infected cells. This suggests that some of the 
nanoparticles that are released from RV-infected 
cells maybe infectious RV particles as these 
supernatants produced more infectious RV particles 
(~73nm) than the arachidin treated cells (~110nm) as 
shown with the plaque forming assays.  This suggests 
that the maturation of the infectious RV particles is 
affected with the addition of the arachidins (A1 and 
A3). Previous studies infecting Caco-2 cells with 
RRV (rhesus monkey rotavirus) have shown the 
presence of extracellular vesicles (EVs) composed of 
exosomes and apoptotic bodies obtained by 
filtration/ultracentrifugation or differential 
centrifugation (Barreto et al., 2010; Bautista et al., 
2015). A recent manuscript has reviewed data that 
show Picornaviridae and Hepesviridae produce virus 
particles in fully host-derived lipid bilayers that  
resemble extracellular vesicles (EV), which are 50 
nm–1 µm vesicles released by infected cells (van der 
Grein et al., 2018). These studies indicate that some 
of the nanoparticles that our study has measured 
maybe EVs, therefore they will be further 
characterized in future studies. 
The nucleus to cytoplasm ratios studies and 
plasma membrane blebbing of the RV-infected 
MA104 cells showed characteristics of apoptosis 
similar to that seen in previous studies 
(Nikoletopoulou et al., 2013), while the appearance 
of RV-infected cells treated with A1 or A3 was 
similar to the control cells (NV, A1 and A3 only).  
This implies cellular alterations to achieve 
homeostasis. 
Additionally, the increased presence of 
autophagosomes in the MA104 cells with A1 alone 
and RV with A1 suggested that A1 modulates 
MA104 cellular homeostasis and RV infections by 
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stimulating cells to utilize the autophagy pathway.  
Autophagy is a conserved mechanism that is a 
safeguard for cellular homeostasis.  It produces 
autophagosomes to degrade damaged proteins in the 
cytoplasm and is believed to be a pro-survival 
pathway (Noguchi and Hirata, 2015). However, 
autophagy can be a form of programmed cell death 
as demonstrated in a study that shows the activation 
of cannabinoid receptors induces autophagy mediate 
cell death through the stimulation of ER stress in 
human glioma cells (Costa et al., 2016).  Autophagy 
is regulated by several cellular signaling pathways 
including class I phosphoinositide 3-kinase (PI3K), 
protein kinase B (PKB)-mammalian target of 
rapamycin complex 1 (mTORC1), and other mTOR-
independent pathways (Chiu et al., 2014).  The 
consequences of the activation of the autophagy 
depends on the types of cells and the stress-inducing 
signals (Kenakin and Christopoulos, 2013; Raehal et 
al., 2005; Rasmussen et al., 2011b, 2011a).   
A recent drug screening study has identified the 
PI3K/mTOR inhibitor, BEZ235, as a regulator of 
both influenza virus production and cellular 
metabolic homeostasis (Smallwood, et al, 2017).  
Proteomic and functional analysis of the primary 
epithelial cells show a regulation of homeostasis in 
the infected cells that changes with the addition of 
BEZ235.  Also, BEZ235 protects mice challenged 
with a lethal dose of influenza. This implies another 
potential antiviral agent has similar effects on both 
the virus and the cells.  It will be interesting to 
determine if A1, A3 and BEZ235 use similar 
mechanism(s) of action. 
Previously, a cannabinoid receptor binding 
study has demonstrated that both A1 and A3 bind to 
CBR1 and CBR2. Moreover, A3 was shown to be a 
competitive receptor antagonist for CBR1, and A1 
antagonized CBR1 agonists by both competitive and 
non-competitive mechanisms (Brents et al., 2012). 
Cannabinoid receptors (CBRs) are G-protein 
coupled receptors (GPCRs) that are present on many 
types of cells.  They control diverse physiological 
functions, including neural processes, cellular 
metabolism, and modulation of cellular activity 
including apoptosis (Bosier et al., 2010). The GPCRs 
have been shown to activate different G proteins to 
inhibit adenylyl cyclase, couple to the mitogen-
activated protein kinase (MAPK) pathway, to couple 
to phospholipase C causing the release of 
intracellular calcium ([Ca]i), and activate 
phosphatidylinositide-3-kinase causing the 
inhibition of voltage-dependent calcium channels 
(ICa)(Kamato et al., 2017; Khan et al., 2016; Neves 
et al., 2002). The presence of CBRs on MA104 cells 
suggests an activation of a receptor-mediated cell 
signaling pathway(s) that could be used to modulate 
an RV infection.  This implies that the addition of A1 
and A3 may initiate biased signaling, which is the 
activation of different signaling pathways or the 
same signaling pathways differently (Ibsen et al., 
2017).  Biased signaling has been defined as the 
model of how different ligands act on the same 
GPCR, in the same tissue, can give rise to markedly 
different cellular responses by stabilizing different 
receptor conformations. The differential signaling 
pathway activation by different agonists can also 
arise as consequences of kinetics.  Changes in the 
timing of dissociation of different ligands may result 
in receptor conformations that favor low affinity 
interactions for a particular receptor/signaling 
molecule pair to produce a signaling cascade (Ibsen 
et al., 2017).  
Also, some of the variability observed in the 
pathways activating kinases downstream of both 
CBR1 and CBR2 may be due to the differential 
expression of the receptors on different cell types. An 
example of this is presented in a study that shows the 
requirement of high receptor expression for the 
activation of  pAkt, but the activation of ERK1/2 is 
not affected by the level of expression of the 
receptors (Cudaback et al., 2010). Future studies will 
explain the influence of different cell types, with 
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different receptor numbers and second messenger 
expressions used in the cannabinoid receptor 
signaling pathways. Biased signaling of GPCR-
directed therapeutics would allow for a more targeted 
approach for antiviral treatments. 
In summary, this study showed that RV-
infected MA104 cells treated with A1 or A3 
exhibited a more normal ultrastructural appearance 
than untreated RV-infected cells; a decrease in the 
number of extracellular infectious RV particles; a 
decrease in structural and nonstructural RV proteins; 
and a shift to a larger size population of extracellular 
nanoparticles.  However, the fact that A1 produced 
numerous autophagosomes while A3 did not, infers 
that different mechanism(s) of action or different 
stimulations of the same mechanism(s) of action 
modulate an RV infection.  This suggests that A1 and 
A3 have anti-RV activity towards different RV 
strains and implies potential broad range therapeutic 
activity on other virus infections that employ similar 
mechanism(s) of action.  Future studies will resolve 
these differences and disclose the mechanism(s) of 
action of A1 and A3 that will illustrate their anti-RV 
therapeutic activity. 
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